Critical Neurologic Dysfunctions: Status Epilepticus and Guillain-Barré Syndrome

  • G. Savettieri
Conference paper


What is the definition of neurocritical care? Daniel F. Hanley from the Johns Hopkins University stated on this point: “Three important aspects of the word critical are time, physiology, and outcome” [1]. The role of time is strictly connected with the progression of the nervous system dysfunction, and with the observation that early treatment of some disorders limits the morbidity and mortality. Concerning the second word of the Hanley’s definition, it is well known that monitoring of key physiologic variables is essential in critical care. What is necessary to define is the physiologic parameters we have to follow for each type of disorder. Finally the outcome, that is the precise definition of the consequences of a given disease by sex, age, type of insult and so on.


Status Epilepticus Plasma Exchange Neurocritical Care Convulsive Status Epilepticus Nonconvulsive Status Epilepticus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Daniel F Hanley (1993) Neurocritical care for coma, intracranial pressure, head injury, and neoplasia. Commentary. Curr Opin Neurol 6: 829–830CrossRefGoogle Scholar
  2. 2.
    Hauser WA (1990) Status epilepticus: epidemiologic considerations. Neurology 40[Suppl 2]: 9–13PubMedGoogle Scholar
  3. 3.
    DeLorenzo RJ, Pellock JM, Towne AR et al (1995) Epidemiology of status epilepticus. J Clin Neurophysiol 12: 316–325PubMedGoogle Scholar
  4. 4.
    Rabinowicz AL, Correale J, Bracht K et al (1995) Neuron-specific enolase is increased after nonconvulsive status epilepticus. Epilepsia 36: 475–479PubMedCrossRefGoogle Scholar
  5. 5.
    DeGiorgio CM, Correale JD, Rabinowicz AL et al (1996) Neuron-specific enolase, a marker of acute neuronal injury is elevated in complex partial status epilepticus. Epilepsia 37: 606–609PubMedCrossRefGoogle Scholar
  6. 6.
    Cranford RE, Leppik IE, Patrick B et al (1979) Intravenous phenytoin in acute treatment of seizures. Neurology 29: 1474–1479PubMedCrossRefGoogle Scholar
  7. 7.
    Towne AR, Pellock JM, Daljin K et al (1994) Determinants of mortality in status epilepticus. Epilepsia 35(1): 27–34PubMedCrossRefGoogle Scholar
  8. 8.
    Young GB, Jordan KG, Doig GS (1996) An assessment of nonconvulsive seizures in the intensive care unit using continuous EEG monitoring: An investigation of variables associated with mortality. Neurology 47: 83–89PubMedCrossRefGoogle Scholar
  9. 9.
    Treiman DM, Meyers PD, Walton NY (1991) Response of overt versus subtle generalized convulsive status epilepticus to intravenous anticonvulsant therapy. (Abstract) Epilepsia 32 [Suppl]37: 93Google Scholar
  10. 10.
    Jordan KG, Young GB, Doig GS (1995) Delays in emergency department (ED) diagnosis and treatment of nonconvulsive status epilepticus (NCSE). (Abstract) Neurology 45[Suppl 4]: A346Google Scholar
  11. 11.
    Lowenstein DH, Alldredge BK (1993) Status epilepticus at an urban public hospital in the 1980s. Neurology 43: 483–488PubMedCrossRefGoogle Scholar
  12. 12.
    Beghi E, Kurland LT, Mulder DW et al (1985) Guillain-Barré syndrome: Clinicoepidemiologic features and effect on influenza vaccine. Arch Neurol 27: 1053–1057CrossRefGoogle Scholar
  13. 13.
    Johnson DE (1982) Guillain-Barré syndrome in the US Army. Arch Neurol 39: 21–24PubMedCrossRefGoogle Scholar
  14. 14.
    Kennedy RH, Danielson MA, Mulder DW et al (1978) Guillain-Barré syndrome: A 42-year epidemiologic and clinical study. Mayo Clin Proc 53: 93–98PubMedGoogle Scholar
  15. 15.
    Ropper AH, Wijdicks EFM, Truax BT (1991) Guillain-Barré syndrome. FA Davis, PhiladelphiaGoogle Scholar
  16. 16.
    Hartung H-P, Pollard JD, Harvey GK et al (1995) Immunopathogenesis and treatment of the Guillain-Barré syndrome-part I and II. Muscle Nerve 18: 137–164PubMedCrossRefGoogle Scholar
  17. 17.
    Rees JH, Soudain S, Gregson NA (1995) Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 333: 1374–1379PubMedCrossRefGoogle Scholar
  18. 18.
    Griffin JW, Ho TW-H (1993) The Guillain-Barré syndrome at 75: the Campylobacter connection. Ann Neurol 34: 125–127PubMedCrossRefGoogle Scholar
  19. 19.
    Hafer-Macko C, Hsieh S-T, Li CY et al (1996) Acute motor axonal neuropathy: an antibody mediated attack on axolemma. Ann Neurol 40: 635–644PubMedCrossRefGoogle Scholar
  20. 20.
    Yuki NT, Taki F, Inagaki T et al (1993) A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 178: 1771–1775PubMedCrossRefGoogle Scholar
  21. 21.
    Arnason BGW, Soliven B (1993) Acute inflammatory demyelinating polyradiculoneuropathy. In: Dyck PJ, Thomas PK, Griffin JW et al (eds) Peripheral neuropathy, 3th edn. WB Saunders, Philadelphia, p 1437Google Scholar
  22. 22.
    Saida K (1996) The immunopathology of Guillain-Barré syndrome. Curr Opin Neurol 9: 329–333PubMedCrossRefGoogle Scholar
  23. 23.
    Truax BT (1984) Autonomic disturbances in Guillain-Barré syndrome. Neurology 4: 462–466Google Scholar
  24. 24.
    Harati Y, Low PA (1990) Autonomic peripheral neuropathies: Diagnosis and clinical presentation. In: Appel SH (ed) Current Neurology. Year Book Medical Publishers, p 105Google Scholar
  25. 25.
    Loffel NB, Rossi LN, Mumenthaler M et al (1977) The Landry-Guillain-Barré syndrome: Complications, prognosis, and natural history in 123 cases. J Neurol Sci 33: 71–79PubMedCrossRefGoogle Scholar
  26. 26.
    McKhann GM, Griffin JW, Cornblath DR et al (1988) The Guillain-Barré Syndrome Study Group: Plasmapheresis and Guillain-Barré syndrome: Analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 23: 347–353PubMedCrossRefGoogle Scholar
  27. 27.
    French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome (1987) Efficiency of plasma exchange in Guillain-Barré syndrome: Role of replacement fluids. Ann Neurol 22: 753–761CrossRefGoogle Scholar
  28. 28.
    Osterman PO, Fagius J, Lundemo G et al (1984) Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 2: 1296–1299PubMedCrossRefGoogle Scholar
  29. 29.
    van der Meché FGA, Schmitz PIM, The Dutch Guillain-Barré Study Group (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 326: 1123–1129PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 1998

Authors and Affiliations

  • G. Savettieri

There are no affiliations available

Personalised recommendations